Albert Do, MD, MPH
Assistant Professor AdjunctCards
About
Research
Publications
2024
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do A, Zahrawi F, Mehal W. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature Reviews Drug Discovery 2024, 24: 171-189. PMID: 39609545, DOI: 10.1038/s41573-024-01084-2.Peer-Reviewed Original ResearchSide effect profileTrial end pointsCombination of therapeuticsReverse many aspectsFatty acid synthase inhibitorGenetic susceptibility factorsPlacebo responseEffect profileFibrosis reversalTreated patientsClinical studiesLiver inflammationSynthase inhibitorLiver diseaseTherapeutic approachesClinical useEnd pointsSteatotic liver diseaseTherapeutic landscapeMetabolic environmentHepatocyte deathSusceptibility factorsChronic overnutritionGlobal epidemicLiverImpact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease
Wong R, Yang Z, Yeoh A, Do A, Ahmed A, Cheung R. Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease. The American Journal Of Gastroenterology 2024, 119: 1841-1848. PMID: 38477465, DOI: 10.14309/ajg.0000000000002760.Peer-Reviewed Original ResearchConceptsImpact of HIV infectionAntiretroviral therapyIncidence of cirrhosisAdverse cardiovascular eventsHIV infectionHepatocellular carcinomaAssociated with greater riskCardiovascular diseaseOverall survivalCardiovascular eventsLiver diseaseSteatotic liver diseaseConcurrent HIV infectionDecreased overall survivalRisk of cirrhosisRisk of liverGreater riskLiver disease progressionPropensity-matched cohortScore-matched cohortCardiovascular disease outcomesUS veteransCardiovascular outcomesDisease progressionPrimary outcomeImpact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among US Veterans With Steatotic Liver Disease
Wong R, Yang Z, Cheung R, Singal A, Do A, Ahmed A, Yeoh A. Impact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among US Veterans With Steatotic Liver Disease. Gastroenterology 2024, 166: 1156-1165.e4. PMID: 38428619, DOI: 10.1053/j.gastro.2024.02.032.Peer-Reviewed Original ResearchConceptsRisk of cirrhosisHigh-risk alcoholIncidence of cirrhosisHigh-risk alcohol useLiver diseaseSteatotic liver diseaseLong-term riskAlcohol Use Disorders Identification Test-ConciseAlcohol useFollow-upRisk of liver disease progressionLow-risk alcohol useAbstractText Label="RESULTS">Liver disease progressionAlcohol use assessmentImpact of alcohol useUS veteransBaseline alcohol useAlcohol use patternsDisease progressionCirrhosisReducing alcohol usePatientsLongitudinal alcohol useNo alcoholChapter 6 Clinical diagnosis and evaluation pathway
Lam R, Banini B, Do A, Lim J. Chapter 6 Clinical diagnosis and evaluation pathway. 2024, 77-100. DOI: 10.1016/b978-0-323-99649-5.00003-0.Peer-Reviewed Original Research
2023
S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program
Do A, Ilagan-Ying Y, Deng Y, Banini B, Lim J, Mehal W. S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program. The American Journal Of Gastroenterology 2023, 118: s1193-s1194. DOI: 10.14309/01.ajg.0000955964.73046.7b.Peer-Reviewed Original ResearchScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosisExercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Chen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseEffects of exerciseFatty liver diseaseHistological outcomesLiver histologyLiver diseaseClinical trialsHistological endpointsSystematic reviewSignificant histopathological improvementNAFLD activity scoreImpact of exerciseIndependent effectsRandom-effects modelSystematic literature searchHistopathological improvementExercise interventionActivity scoreClinical endpointsPooled estimatesMeta-AnalysisTotal participantsLiterature searchComparison groupSa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CARE
Ilagan-Ying Y, Tseng R, Valido K, Bollinger B, Kelly M, Do A. Sa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CARE. Gastroenterology 2023, 164: s-1286-s-1287. DOI: 10.1016/s0016-5085(23)03992-6.Peer-Reviewed Original ResearchLean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI
Do A, Lim J. Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI. Hepatology 2023, 78: 6-7. PMID: 36896961, DOI: 10.1097/hep.0000000000000360.Peer-Reviewed Original ResearchBroadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine
Do A, Xu J. Broadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine. Digestive Diseases And Sciences 2023, 68: 725-728. PMID: 36670325, DOI: 10.1007/s10620-023-07827-2.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)
HIC ID2000027577RoleSub InvestigatorPrimary Completion Date11/01/2022Recruiting ParticipantsGenderBothAge18 years - 75 years
Academic Achievements & Community Involvement
News
News
- May 31, 2022Source: Healio
Surge in alcohol-related disease during pandemic reveals unmet need for treatment
- September 25, 2021Source: Eat This! Not That!
Warning Signs You're Becoming Obese
- May 10, 2021Source: Everyday Health
Can You Lose Weight by Drinking Water?
- April 12, 2021
Meet Yale Internal Medicine: Albert Do, MD, MPH, Assistant Professor of Medicine (Digestive Diseases)
Get In Touch
Contacts
Email
Appointment Number
Clinic Fax Number
Mailing Address
Yale School of Medicine
Department of Medicine (Digestive Diseases), P.O. Box 208019
New Haven, CT 06520-8019
United States